NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, version 3.2020 Guidelines


Authors: Gradishar, W. J.; Anderson, B. O.; Abraham, J.; Aft, R.; Agnese, D.; Allison, K. H.; Blair, S. L.; Burstein, H. J.; Dang, C.; Elias, A. D.; Giordano, S. H.; Goetz, M. P.; Goldstein, L. J.; Isakoff, S. J.; Krishnamurthy, J.; Lyons, J.; Marcom, P. K.; Matro, J.; Mayer, I. A.; Moran, M. S.; Mortimer, J.; O'Regan, R. M.; Patel, S. A.; Pierce, L. J.; Rugo, H. S.; Sitapati, A.; Smith, K. L.; Smith, M. L.; Soliman, H.; Stringer-Reasor, E. M.; Telli, M. L.; Ward, J. H.; Young, J. S.; Burns, J. L.; Kumar, R.
Title: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, version 3.2020
Abstract: Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 18
Issue: 4
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2020-04-01
Start Page: 452
End Page: 478
Language: English
DOI: 10.6004/jnccn.2020.0016
PUBMED: 32259783
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 May 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Chau Dang
    272 Dang